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Surface tension–area diagramThe high costs of artiﬁcial pulmonary surfactants, ranging in hundreds per kilogram of body weight, used for
treating the respiratory distress syndrome (RDS) premature babies have limited their applications. We have ex-
tensively studied soy lecithins and higher alcohols as lipid alternatives to expensive phospholipids such as DPPC
and PG. As a substitute for the proteins, we have synthesized the peptide Hel 13-5D3 by introducing D-amino
acids into a highly lipid-soluble, basic amphiphilic peptide, Hel 13-5, composed of 18 amino acid residues. Anal-
ysis of the surfactant activities of lipid-amphiphilic artiﬁcial peptide mixtures using lung-irrigated rat models re-
vealed that a mixture (Murosurf SLPD3) of dehydrogenated soy lecithin, fractionated soy lecithin, palmitic acid
(PA), and peptide Hel 13-5D3 (40:40:17.5:2.5, by weight) superior pulmonary surfactant activity than a com-
mercially available pulmonary surfactant (beractant, Surfacten®). Experiments using ovalbumin-sensitized
model animals revealed that the lipid-amphiphilic artiﬁcial peptide mixtures provided signiﬁcant control over
an increase in the pulmonary resistance induced by premature allergy reaction and reduced the number of
acidocytes and neutrophils in lung-irrigated solution. The newly developed low-cost pulmonary surfactant sys-
tem may be used for treatment of a wide variety of respiratory diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The pulmonary surfactant is a lipid–protein complex secreted from
the alveolar cells and plays an essential role in the pulmonary function
by reducing the surface tension [1–3]. The pulmonary surfactant con-
tains phospholipid and neutral fat such as cholesterol and triglycerol.
Phospholipids such as dipalmitoylphosphatidylcholine (DPPC) and
phosphatidylglycerol (PG) are considered to be essential to the surfac-
tant activity [2]. In addition, surfactant proteins (SPs) SP-A, SP-B, SP-C
and SP-D account for approximately 5% of the total pulmonary
surfactants [1]. Among these surfactant proteins, SP-B and SP-C are im-
portant and induce surfactant activities for pulmonary respiration [4,5].
Since SP-B localized to the surface of the cell membrane and SP-C
is membrane resident, their activities in the pulmonary surfactantrome; DPPC, dipalmitoyl-L-α-
lcholine; egg PG, egg yolk
acid; RDS, respiratory distress
ysical Chemistry, Faculty of
rsity, 2825-7 Huis Ten Bosch,
686.
dexenglish.html (O. Shibata).differ from their action modes. Their roles in the pulmonary surfactant
activities remain largely unknown. It is thought that the proteins
catalyze the migration of lipids from the monolayer membrane to
the bilayer membrane occurring at the air–liquid interface of the
lung surface at the time of respiration [4,5]. A recent study found
that the interaction between the basic properties of PG and SP is of
signiﬁcance [6].
We have considered that a mixture of an amphiphilic basic peptide
having both of amembrane-surface staying type and amembrane span-
ning type with an appropriate phospholipid can provide pulmonary ac-
tivities.We have reported the synthesis of a basic peptide, Hel 13-5, that
was amphiphilic and highly lipid-soluble [7]. This peptide is conﬁgured
in such a manner that the lipid-soluble and the water-soluble portions
are separated from each other along the helical axis (Fig. 1). Similarly
to SP-B, this peptide is considered to occupy the cell surface. Experi-
ments using liposomes showed that lipid-soluble portion of Hel 13-5
was able to penetrate into the acidic and neutral phospholipid mem-
branes [8]. Further, when the lipid was mixed with the peptide at a
rate of 5-3 (lipid):1 (peptide), the peptide formed a nanotube together
with the lipid [9,10]. Hel 13-5 is similar to SP-C in that the peptide is in-
volved in the interaction with the lipid-soluble portion of the lipid. The
surface tension–surface area curve (hysteresis curve) of the mixture of
the peptide with the lipid constructed using the Wilhelmy surface
Fig. 1. Primary structure of peptides and α-helical wheel representation of Hel 13-5.
Underlines represent D-amino acids.
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DPPC/PG/PA/Hel 13-5 system had a high pulmonary surfactant activi-
ty [11]. The experiments on the system further revealed that the peptide
and PG are squeezed out in the form of a bimolecular structure (or
surface-associated reservoir) from the monomolecular membrane in
the course of compression and DPPC is stayed on the monomolecular
membrane [11–13]. Recently, PA was found to improve the ordering
of DPPC at the surfacewhile stabilizing the surface-associated reservoirs
below the surface [14]. Further, it has been shown that these lipid com-
ponents control the secondary structures of the peptide during the com-
pression and expansion of the surface monolayers, demonstrating the
importance of speciﬁc interaction between anionic lipids and cationic
peptide in the pulmonary surfactant system [15–17]. Notably, a hydro-
genated soy lecithin/soy lecithin/PA/Hel 13-5 (40/40/17.5/2.5, by
weight) showed surfactant activity comparable to that of beractant
(Surfacten®), a commercially available surfactant [18]. This indicated
that the soy lipid can be used as an inexpensive substitute for DPPC
and PG.
The basic amphiphilic peptide interacts with the biomembrane and
exhibits various properties, including antibacterial activity, membrane
fusion, and hemolysis [19]. The basic and amphiphilic surfactant protein
SP-B not only has the surfactant activity, but also plays a role in control-
ling the lung inﬂammation [20] and exhibits antibacterial property [21].
One study found that a derivative of SP-B might be effective against
pneumonia. We have synthesized the basic and amphiphilic peptide
Hel 13-5 that possesses a membrane fusion activity, channel formation,
and hemolytic activity [7]. However, its complex with the lipid loses its
activities at the above rate.
It has been reported that the introduction of a D-amino acid into
the basic and amphiphilic peptide with the hemolytic and antibacterial
activities improves the membrane speciﬁcity and selectivity and de-
creases the hemolytic activity while maintaining its strong antibacterial
activity [22,23]. There is also the recent report of an increased selectivity
between tumor cells and normal cells [24]. Therefore, we prepared two
compounds, {D-L 7,14, K8} Hel 13-5 (Hel 13-5D3) and {D-L 7,11,14,16, K8}
Hel 13-5 (Hel 13-5D5) (Fig. 1), by replacing a portion of the amino
acid sequence of the peptideHel 13-5withD-amino acids. The inﬂuence
of the amino acid replacement on the in vitro and in vivo pulmonary
surfactant activities of the hydrogenated soy lecithin/soy lecithin/PA/
synthetic peptide (40/40/17.5/2.5, by weight) preparations was
assessed. This assessment was made based on the hysteresis curve,
the recovery of pulmonary compliance in lung-irrigated rats, and
the asthma control effects in ovalbumin-sensitized model animals.
The experimental results revealed that the 18-amino acid peptide
containing the D-amino acids was more active than the commercially
available pulmonary surfactant (Surfacten®). Experiments with
ovalbumin-sensitized model animals further demonstrated that an in-
duced elevation of a pulmonary resistance (early phase) can be
suppressed.
In this study, we examined the possibility of applying the pulmonary
surfactant system broadly to the pulmonary diseases caused by pulmo-
nary surfactant deﬁciency.2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (egg PC, purity N 99%) and egg
phosphatidylglycerol (egg PG, N99%) were purchased from Avanti
Polar Lipids, Inc. and Sigma, respectively. Hydrogenated soy lecithin
(SLP White H), fractionated soy lecithin 70 (fractional lecithin SLP-
PC70), and hydrogenated soy lecithin 70H (prepared by hydrogenating
soy lecithin SLP-PC70) were purchased from True Lecithin Mfg. Co., Ltd.
(Mie, Japan). Surfacten®was purchased fromMitsubishi Pharma Corp.,
(Tokyo, Japan). All other lipids were purchased fromWako Pure Chem-
ical Industries (Osaka, Japan). The lipid–peptide mixtures correspond-
ing to Exosurf® and Surfaxin were prepared in our laboratory to
yield a dipalmitoylphosphatidylcholine (DPPC, 99%)/1-hexadecanol
(HD, 98%)/tyloxapol (84/16/0.25, by weight) system and a DPPC/egg
PG/palmitic acid (PA, N98%)/KL4 (75/25/10/3, by weight) system,
respectively. As model pulmonary surfactant preparations, ﬁve mix-
tures were used; Murosurf L: 1-octadecanol (OD, N98%)/egg PC/PA
(35/40/25), Murosurf SL: SLP White H/SLP-PC70/PA (40/40/20,
by weight), Murosurf SLP: SLP White H/SLP-PC70/PA/Hel 13-5 (40/40/
17.5/2.5), Murosurf SLPD3: SLP White H/SLP-PC70/PA/Hel 13-5D3
(40/40/17.5/2.5), and Murosurf SLPD5: SLP White H/SLP-PC70/PA/Hel
13-5D5 (40/40/17.5/2.5).
2.2. Synthesis of peptides
The peptides were synthesized using an automated synthesizer
(PerSeptive Biosystems) by Fmoc solid phase synthesis method of the
continuous ﬂow type using Fmoc-Leu-PEG resin (Fmoc-Leu-OH resin,
0.21 mmol/g; Watanabe Kagaku K.K.) as a starting material [7].
The crude peptide synthesized was then dissolved in 30% acetic
acid and subjected to chromatography using a Sephadex® G-25
column. The peptide portions elutedwere collected and further puriﬁed
with reverse-phase high-throughput liquid chromatography (HPLC)
(COSMOSIL 5C18-AR 20 × 250 mm) using 0.1% TFA/water and
acetonitrile as solvents. The purity of the peptide product was con-
ﬁrmed by the presence of a single peak in its HPLC (COSMOSIL 5C18-
AR 4.6 × 150 mm) proﬁle and by the TOF-Mass analysis method
(Voyager type; PerSeptive Biosystems, Tokyo). Water containing 0.1%
TFA and acetonitrile were used as a solvent for elution.
2.3. Circular dichroism (CD) measurement
The circular dichroism (CD) spectrum in the wavelength region of
196–260 nm was recorded at 25 °C on a J-700 spectrometer (J-700;
Nihon Bunkou, K.K., Hachiouji, Tokyo) using a quartz cell (with water
jacket) of cell length 0.1 cm. The measurements were repeated four
times.
A peptide solutionwas prepared by dissolving approximately 2mg of
the peptide in 2 mL of 20 mM TES Buffer containing 150 mM NaCl. The
concentration of the peptide solutionwas estimated from the absorbance
of the solution at 280 nm (molar ellipticity of Trp, 5000 cm/mol). The
peptide–lipid solution was prepared as described in the following sec-
tion. The suspensionswere sonicated for 10min (×3) by using a titanium
tip sonicator under ice-cold conditions and nitrogen ﬂowing.
2.4. Preparation of sample (peptide–lipid mixture)
An amount of each of the peptide, lipid, and aliphatic acid was
weighed and dissolved in a mixture of chloroform/methanol. To
the resulting solution, the peptide was added to the amount to 2.5% or
5% w/w. The peptide–lipid solution was purged with nitrogen (N2) gas
and dried under reduced pressure to yield a dry ﬁlm coating on the sur-
face of the vessel. A physiological salinewas added to the vessel and the
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as a sample.
2.5. Processes for formation experiments of surface tension–area diagram
The surface tension was measured with a Wilhelmy Balance
(AcomaMedical Industry Co., Ltd., Japan). A Teﬂon®-coated water ves-
sel (78 × 138 × 30 mm) was ﬁlled with physiological saline to form a
closed liquid surface. The air–liquid interface of the liquid surface was
developed using 100 μg of the peptide–lipid mixture and was allowed
to stand for 3 min to permit the mixture to spread thereon spontane-
ously. Variation in the surface tension during this period was recorded
as the surface spreading rate with a platinum plate hanging vertically
in the vessel. The surface area of the monolayer formed in 3 min,
which repeatedly spread and compressed alternately at a speed of
3 min per cycle (maximum area of 45 cm2 to the minimum area of
9 cm2) was recorded. The surface tension acting onto the platinum
plate was converted into electrical signals with a force converter. The
electrical signals, together with the variation in the surface area, were
automatically recorded continually with an X-Y recorder. The recording
was continued until variation could no longer be detected. The curves
for all systems during the seventh cycle, which was close to the equilib-
rium state, are represented in this study.
2.6. Pulmonary surfactant-deﬁcient animal models
A pulmonary surfactant-deﬁcient rat model was generated by irri-
gating the lung of the Wistar rats with warm physiological saline and
by ventilating the animals artiﬁcially under 100% oxygen. The model
rats were administered with the artiﬁcial pulmonary surfactant prepa-
ration and its effects on the prolongation of life and pulmonary compli-
ance were examined. Three pulmonary surfactants were used as
controls. These are, Surfacten® that is derived from the bovine pulmo-
nary surfactant and being currently under clinical trial, Surfaxin® that
is composed of DPPC as a major component and synthetic peptides
consisting of lysine (K) and leucine (L) (KL24), and colfosceril palmitate
(Exosurf®),which is composed solely of the lipid systemand containing
no peptide. Physiological saline with no pulmonary surfactant also
served as a control. Surfacxin® and Exosurf® were synthesized in our
laboratory according to reported methods. The rat lung was irrigated
until its pre-irrigation pulmonary compliance of ca. 0.60 mL/cm H2O
dropped to ~0.2 mL/cm H2O. After the formation of the pulmonary
surfactant-deﬁcient rat model was conﬁrmed, the rats were subjected
to experiments for the administration of various pulmonary surfactants.
A group of six rats or more was used for testing the effects of each
pulmonary surfactant. Experimental details have been described else-
where [18]. The Tukey–Kremermethodwas used for statistical analysis,
P b 0.05 was considered statistically signiﬁcant.
2.7. Experimental conditions and method of asthma models
For generating rat models of asthma the Brown Norway rats were
sensitized with egg white albumin (OVA), which elevated the pulmo-
nary resistance upon inhalation. To measure pulmonary resistance
(RL), the rats were anesthetized by intraperitoneal administration
of urethane (1 g/kg, 25% wt/vol). The RL was monitored using a
PULMOS-II system (M.I.P.S., Osaka, Japan) [25]. Sensitized rats were ex-
posed three times to OVA according to the methods of Abe et al. [26].
Animals were pre-treated by administering 0.1 mL (20 mg/mL) of
each of theMurosurf SL, Murosurf SLP, Murosurf SLPD3, and Surfacten®
compositions into the respiratory tract. After 10 min, the animals were
sensitized with inhaled OVA. The pulmonary resistance was measured
periodically according to the method of Abe et al. [26]. The effects on
asthmawere assessed by examining the ability of the surfactants to sup-
press the enhancement in the pulmonary resistance.After the ﬁnal measurement of the pulmonary resistance,
bronchoalveolar lavage ﬂuid was collected via the tracheal cannula
using 2 × 10 mL of saline containing 1 mM EDTA. The ﬂuid collected
was centrifuged at 300×g for 5min at 4 °C and the cell pellet was resus-
pended in 1.0 mL sterile saline containing 0.2% rat serum. The total cell
count was determined by adding an equal volume of trypan blue stain
and then counting the cells under a light microscope. The differential
cell count was carried out using a smear preparation stained with Diff-
Quik (International Reagents Corp., Kobe, Japan). Two hundred cells
were counted at random under ×200 magniﬁcation. The cells were
identiﬁed by their morphologies.
The Tukey–Kremer method was used for statistical analysis. P b 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Designing highly speciﬁc peptides related to Hel 13-5 containing
D-amino acids
As described earlier [7], we prepared the amphiphilic peptide Hel
13-5 with the ideally separated hydrophobic and hydrophilic parts,
when it was drown in a helical wheel diagram (Fig. 1). In the presence
of a lipid membrane, the lipid-soluble portion of Hel 13-5 penetrates
deeply into the bimolecularmembrane [8]. This provides a high pulmo-
nary surfactant activity that is comparable to the artiﬁcial pulmonary
surfactant derived from the pig lung, but Hel 13-5 shows a stronghemo-
lytic activity upon single application in the absence of lipids [18]. Previ-
ous studies have shown that the introduction of D-amino acids into the
amphiphilic peptide forces a conformational change and causes a de-
crease in hydrophobicity, leading to reduced hemolytic activity [22,
23]. Therefore, we introduced D-amino acids into Hel 13-5 to suppress
its hemolytic activity. The D-amino acids were introduced at optional,
but well-balanced positions, and the D-amino acid content of the pep-
tide was set at 20% to 30% (Fig. 1).
3.2. Conformation and lipid-solubility of peptides
To understand the changes in the structure and properties of the
peptide brought about by the introduction of the D-amino acids, we an-
alyzed their CD spectra and reverse-phase HPLC proﬁles (Fig. 2). The CD
spectra revealed that the peptide Hel 13-5 assumed an α-helical
structure in aqueous solution, whereas the peptides Hel 13-5D3 and
Hel 13-5D5 each assumed a random structure (Fig. 2A). In the presence
of neutral and acidic liposomes, Hel 13-5D3 showed a β-structure-
like CD spectrum containing partially α-helical structures, while Hel
13-5D5 did not show any speciﬁc structure. Measurements in the pres-
ence of soy lecithin indicated that Hel 13-5D3 was in a helix-like shape
with a considerablyweakmolar ellipticity, whereasHel 13-5D5 showed
weakmolar ellipticity in all wavelengths measured (Fig. 2). As opposed
toHel 13-5, Hel 13-5D3 andHel 13-5D5 failed to assume an amphiphilic
α-helical structure in buffer solution, likely because of the presence of
D-amino acid moieties in their structures. However, in the presence of
lipids, Hel 13-5D3 shows secondary structures such as α-helical and
β-structure. In contrast, Hel 13-5D5 did not assume any speciﬁc
structure in the media examined. Thus, it was found that the
secondary structure is controlled both by the environmental lipids and
by the D-amino acid content of the peptide sequences. The interaction
of amphiphilic α-helical peptides with the biomembrane constituents
has been previously evaluated for the hydrophobicity related to the
composition of the α-helical structure [7,8].
The reverse phase (C18) HPLC analysis was carried out to assess the
hydrophobicity of the peptide. In general, retention time increases
with hydrophobicity [27]. The retention time decreased with increasing
D-amino acid content, indicating that the synthetic peptide–lipidmono-
layer interaction became weaker with the introduction of D-amino
acids, which altered the secondary structure of the peptide (Fig. 2B).
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Fig. 2.CD (A) andHPLC (B) data of Hel 13-5 peptide containing theD-amino acid. (A)Hel 13-5 (solid line), Hel 13-5D3 (broken line), andHel 13-5D5 (two-dot chain line). i) in buffer, ii) in
the presence of neutral lipids (egg PC), and iii) in the presence of acidic lipids (egg PC/egg PG= 3/1), and hydrogenated soy lecithin/fractionated soy lecithin PC70/PA/peptides (9/9/1/1,
by weight) in iv). Peptide and lipid concentrations were 10 μM and 100 μM, respectively.
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A stablemutual transfer from themonolayermembrane to the bilay-
er membrane is proposed as the basis of the expression of the pulmo-
nary surfactant activity [28]. Phospholipids are essential for this
transfer. The pulmonary surfactant is composed of the protein and the
lipid. The protein is considered to smoothly catalyze the transfer be-
tween the monolayer membrane and the phospholipid bilayer on the
air–liquid interfaces of the alveoli. This transfer can be readily observed
by constructing the surface tension–surface area curve (hysteresis
curve) with the Wilhelmy surface tensiometer representing a variation
in the respiratory pressure of the lung [29]. In general, a faster drop in
the surface tension or a faster expansion of the surface at the time of
compression or indicates better activity in vivo. In other words, the
greater the area to be formed by the hysteresis curve or the smaller
the surface tension at the time of compression, the higher the activity.
The natural pulmonary surfactant contains a large amount of DPPC
and PG. We have previously used soy lecithin as substitutes for suchFig. 3. The surface tension and the surface area curves in a soy lecithin lipid and peptide
mixture system.expensive lipids [18]. In this study, we have used lipid mixture systems.
Fig. 3 shows a hysteresis diagram of the D-amino acid-containing pep-
tide–lipid mixture systems. In the system containing soy-been lipids,
Hel 13-5D3 hysteresis curves, compared with those of Surfacten® and
the minimum surface tension (13 mNm−1), did not amount to that of
Surfacten®. Hel 13-5D5 showed amore deformed curve. These indicate
that Hel 13-5D3 may have more favorable surfactant activity than Hel
13-5D5.3.4. Assessment of pulmonary surfactant activity using lung-irrigated rat
models
Assessments for the pulmonary surfactant activity of the peptide–
lipid systems were made on the basis of the pulmonary compliance
using lung-irrigated rabbit as an RDS model [30]. In this study, the rat
models were generated by irrigating the lungs ofWistar rats with phys-
iological saline. Pulmonary surfactant was administered tomeasure the
pulmonary function (compliance). The results are shown in Fig. 4. Pul-
monary surfactants are considered better when the values of the com-
pliance rose faster and higher immediately after the administration of
the pulmonary surfactant. Surfacten® raised its compliance steadily im-
mediately after administration and reached a constant compliance in
approximately 2 h.
Themixture system composed of Hel 13-5D3 and the lipidMurosurf
SLPD3 showed similar trends as that of Surfacten®, but reached rather
higher values at 0.5–1 h. This suggested that the recovery of the pulmo-
nary functions was better than that with Surfacten®. The mixture sys-
tem composed of Hel 13-5D5 and the lipid Murosurf SLPD5 produced
a weaker recovery of the pulmonary functions.
The peptide Hel 13-5D3 we have developed performed better
than the mixture system composed of the peptide Hel 13-5 containing
no D-amino acids and the less expensive lipid Murosurf SLP. An
artiﬁcial pulmonary surfactant (Surfaxin) developed as a peptide-lipid
mixture system contains KL4 as a peptide. However, its surfactant
Fig. 4. Recovery of the pulmonary function by various pulmonary surfactants. Serial mea-
surements of recovery ratio of compliance (Crs) of respiratory system are shown. Recov-
ery ratio of Crs was calculated using the formula: (recovery ratio of Crs) = (Crs after
surfactant treatment) / (Crs after lung lavage but before surfactant treatment). The data
represents the mean ± S.D. *P b 0.05 vs. surfactant treatment group.
Fig. 6.A cytological analysis of inﬂammatory cells in bronchoalveolar ﬂuid on inhaled
D-amino acid-containing peptide/lipid mixture. (A) The total cell number of leukocyte
after double OVA challenges. (B) The number of differential cells in leukocyte. Bar graves
aremarked as follows: eosinophil (dots), neutrophil (slanting lines),macrophage (white),
and lymphocyte (black).
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tide Hel 13-5D3.
3.5. Results of experiments with asthma models
It has been reported that the exogenous surfactant administration
signiﬁcantly improved lung function in the patients during an asthmatic
attack [31]. Inhaled synthetic surfactant (Pumactant, Britannia Pharma-
ceuticals Ltd. Redhill, UK) abolished the early allergen-induced response
in asthma [32]. Thus, we examined whether D-amino acid-containing
peptide-lipid mixture abolished the symptoms in rats sensitized with
egg white albumin (OVA). When compared with controls, Murosurf
SL, Murosurf SLP, Murosurf SLPD3, and Surfacten® signiﬁcantly sup-
pressed the enhancement of resistance to the respiratory tract induced
by OVA in 45 min after the administration of OVA (Fig. 5).
After the experiments were terminated, the lung-irrigated solution
was subjected to cytodiagnosis of leukocytes and the cell numbers
were estimated (Fig. 6A). When compared to that in non-sensitized
rats, the number of leukocytes increased in rats sensitized with OVA.
Notably, in rats administered with Murosurf SLPD3 before the adminis-
tration of OVA, the number of leukocytes was lower. Murosurf SL also
decreased the number of leukocytes, while Murosurf L had no effects
on the number of leukocytes (data not shown).
Cellular differentiation in the lung-irrigated solution was examined
(Fig. 6B). When compared to non-sensitized rats, the rats administered
with each of the surfactants, Murosurf SL, Murosurf SLP, Murosurf
SLPD3, and Surfacten®, caused an increase in the number of acidocytes
and neutrophils, and a decreased in the number of macrophages. Ad-
ministration of Murosurf SLPD3 before the sensitizing with OVA de-
creased the number of acidocytes while increasing the number of
macrophages. Murosurf SL also decreased the number of acidocytes
and increased the number of macrophages. Murosurf L had no effectsFig. 5. The time courses of pulmonary resistance (RL) changes on inhaled D-amino acid-
containing peptide–lipid mixture with asthma model rats.on the number of the acidocytes, indicating that peptidesmaybe impor-
tant for decreasing the number of acidocytes and increasing macro-
phage counts.
3.6. Hemolytic activity
The hemolytic activity of Hel 13-5 and Hel 13-5D3 increased in a
concentration-dependent fashion and thehemolytic level reached near-
by 100% at approximately 20-μMconcentration of the peptide. The pep-
tide Hel 13-5D5 increased the hemolytic activity to its maximum level
of 35% at 30–50 μM concentrations and in a concentration-dependent
fashion within the range of 50–70 μM (ﬁgure not shown).
4. Discussion
The amphiphilic structure with the ideally separated hydrophobic
and hydrophilic parts has the speciﬁc hydrophobic–hydrophilic balance
2051Y. Nakamura et al. / Biochimica et Biophysica Acta 1838 (2014) 2046–2052(HHB) depending on amino acid species. The HHB determines the
three-dimensional structure, stability, and physiological functions of
proteins and peptides [7,33]. It is shown that the structure of the
water-soluble residues scatter (e.g. KL4) is more important in the high
spreading effect than the ideal amphipathic structure of Hel 13-5, in
which the helical structure is built up.
Introduction of D-amino acids into a portion of these amphiphilic
peptides caused changes in the secondary structure of the peptide, lead-
ing to signiﬁcant changes in their physiological activity. Shai et al. re-
ported that introduction of D-amino acids into an amphiphilic peptide
with antibacterial and hemolytic activities caused no change in the an-
tibacterial activity while losing only the hemolytic activity [22]. Further,
these peptides were less toxic to normal cells and selectively acted on
the tumor cells alone, leading to the possibility of developing new
anti-tumor chemotherapeutic agents [24]. This was likely due to the
differences in the mechanism of action the peptides toward cell
membranes.
In this study, we synthesized the D-amino acid-containing peptides
with the goal of achievingmembrane speciﬁcity. The D-amino acids in-
ﬂuenced the structure and lipid solubility. These inﬂuences were con-
sidered to have originated from the three-dimensional restrictions on
the freedom of movement of amino acid residues in the peptide struc-
ture. The results of the CD spectralmeasurements led to the assumption
that the originalα-helical structure in a buffer solutionwould be broken
into a random-like structure resulting in a partial breakdown of the am-
phiphilic conﬁguration and causing a decrease of lipid solubility. In the
presence of the lipid, the peptide is considered to assume a new struc-
ture. Although the peptide produced a curve indicative of β-structure,
the structure is yet to be determined. A double minimum indicative of
a helix shape was shown in the presence of the soy lipid. However,
the intensity was lower than that expected for a usual helical structure,
suggesting that structure changed considerably in the presence of the
lipid.
Among the compounds synthesized in this study, Hel 13-5D3 and
Hel 13-5D5 showed similar hysteresis curves in a mixture with the
soy lipid to Surfacten (Fig. 3). In particular, the surface activity of the
Hel 13-5D3 preparation was better in that the curve for Murosurf
LPD3 exhibited lower (minimum) surface tension during the compres-
sion cycle than that for Murosurf LPD5. The Hel 13-5D3 preparation
also demonstrated a high pulmonary surfactant activity as indicated
by the results of the pulmonary compliance experiments using
the lung-irrigated rats. The pulmonary surfactant activity of the above
peptide was superior to that of Hel 13-5 and surpassed that of
Surfacten®.
It has been reported that the pulmonary surfactant activity of a
21-amino acid peptide showing an amphiphilic property along an
α-helical axis was lower than that of the non-amphipathic KL4 [34].
Therefore, it can be considered that the reduced lipid solubility
caused by the structural changes that occurred following the intro-
duction of the D-amino acids into the peptide backbone would con-
tribute to the enhanced surfactant activity of Hel 13-5D3. Results of
our ﬂuorescence experiments suggested that Hel 13-5D3 inserts it-
self deep into the lipid membrane (data not shown).
In this study, we used the inexpensive soy lecithin for preparing the
lipid/Hel 13-5D3system as a lipid substitute for expensive DPPC and PG.
Soy lecithin is used for treating hyperlipidemia and is not toxic to the
tissues. Artiﬁcial animal lung-derived surfactants show antigenicity
and have potential risk of infection such as BSE. In contrast, the artiﬁcial
pulmonary surfactant we have developed can be safely used as an agent
for treating respiratory distress syndromes (RDS) of newborn babies.
Therefore, the newly synthesized peptides are candidate compounds
for use as artiﬁcial pulmonary surfactants.
As the D-amino acid-containing peptides are synthesized by solid
phase automated synthesis method, large-scale production is difﬁcult
and costs of production are somewhat high. A large-scale production
of the peptides is also feasible by liquid phase peptide synthesismethods. We have developed methods for the liquid phase synthesis
of Hel13-5D3.
If the cost of pulmonary surfactants is low, they can be used to treat
adults with acute respiratory distress syndrome (ARDS) as well as to
newborn babies with RDS [35]. Studies have shown that the pulmonary
surfactant can be used to temporarily treat ARDS with no effect on the
prolongation of life [34]. The reports of phase II experiments on some ar-
tiﬁcial pulmonary surfactants showed that their application in treating
ARDS could provide temporary improvements, yet no improvement in
the progress [36]. It has been reported that the enhancement of surfac-
tant functions using the surfactant protein SP-B in endotoxin lung injury
animal models could protect the lung from injuries and that the surfac-
tant with KL4 mimic of SP-B could prevent hyperoxide and LPS-induced
lung injury [37]. These problems are debatable. Furthermore, it was
temporarily recognized that ARDS accompanied injury of functions of
the pulmonary surfactant and the pulmonary surfactant supplement
therapy had the effect on recovery of the respiratory functions. The
strategy of treating the cause of ARDS is considered to lead to the
prolongation of life by the use of pulmonary surfactant to improve the
respiratory functions and consequently protect the lung from barotrau-
ma accompanied by a respirator and from oxygen toxicity. Considering
such observations, the pulmonary surfactant can be applied easily to re-
duce an occurrence of respiratory distress only if it would be inexpen-
sive in terms of production and expenses for administration.
Results of our experiments using asthma models suggested that the
Hel 13-5D3/soy lipid mixture system could be used for treating asthma.
Reduced number of acidocytes and neutrophils in the lung-irrigated
solution of model animals treated with the Hel 13-5D3/soy lipid
mixture suggested that the system could be used for controlling the al-
lergic inﬂammation. Similar effects were also obtained with SP-B and
KL4/surfactant mixture [20]. It was reported that the administration of
the pulmonary surfactant was effective in allergy-sensitized model ani-
mals and that it provided relief from introsusception attack of advanced
bronchial asthma.
In this study, we showed that the new pulmonary surfactant sys-
tems we developed are inexpensive and nontoxic, and they can be
used to treat asthma in addition to ARDS. Furthermore, the new pulmo-
nary surfactants posed no risk of antigenicity or infection, as opposed to
the pulmonary surfactants derived from animals. Our pulmonary sur-
factants are entirely synthetic, which is why that they can be prepared
with high integrity on a large scale. Our development can be used to
greatly improve present medicinal technology, along with RDS and
ARDS treatment strategies.
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